Octagon Capital invests in public and private healthcare companies globally.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Octagon Capital invests in public and private healthcare companies globally. Octagon Capital focuses on strategic long-term investments and strive to work with our portfolio management teams as partners.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2021 | Affinia Therapeutics | Series B | 0 |
5/2021 | Hummingbird Bioscience | Series C | 0 |
5/2021 | Numab | Series C | 110.6M |
4/2023 | Alebund Pharmaceuticals | Series C | 0 |
6/2021 | ArriVent Biopharma | Series A | 81M |
2/2022 | ArriVent Biopharma | Series A | 69M |
9/2021 | Alebund Pharmaceuticals | Series B | 0 |
12/2022 | ArriVent Biopharma | Series B | 0 |
11/2021 | Allorion Therapeutics | Series A | 0 |
8/2022 | Bluejay Therapeutics | Series B | 0 |
3/2021 | Immune-Onc Therapeutics | Series B | 0 |
4/2021 | Forge Biologics | Series B | 120M |
5/2021 | Vedere Bio ll | Series A | 0 |
5/2021 | NiKang Therapeutics | Series C | 200M |
3/2021 | Arctic Vision | Series B | 0 |
12/2021 | AnHeart Therapeutics | Series B | 0 |
11/2021 | Edge Medical Robotics | Series C | 0 |
3/2021 | Hanyu Medical | Series D | 76.9M |
3/2021 | Aktis Oncology | Series A | 72M |
3/2021 | StrideBio | Series B | 0 |
8/2022 | Aktis Oncology | Series A | 0 |
2/2022 | ArriVent Biopharma | Series A | 0 |
12/2021 | AnHeart Therapeutics | Series B | 0 |
11/2021 | Allorion Therapeutics | Series A | 0 |
11/2021 | Edge Medical Robotics | Series C | 0 |
9/2021 | Alebund Pharmaceuticals | Series B | 0 |
6/2021 | ArriVent Biopharma | Series A | 0 |
5/2021 | NiKang Therapeutics | Series C | 0 |
5/2021 | Numab | Series C | 0 |
5/2021 | Vedere Bio ll | Series A | 0 |
5/2021 | Hummingbird Bioscience | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|